variomobil station trolley

Product Description EarlyTect Colon Cancer Test was approved by the Korea Ministry of Food and Drug Safety through clinical trials at Yonsei Medical Center, Severance Hospital, and Severance Check-up Center for eligible subjects, 585 men and women aged 30 to 80. Clinical trials using fecal DNA demonstrated that CRC can be diagnosed with 90% sensitivity and specificity. EarlyTect Colon Cancer Test is a qualitative real-time PCR test that measures methylated Syndecan-2, a biomarker clinically related to precancerous lesions of CRC, in stool DNA to diagnose colorectal cancer. This product is not intended to confirm colorectal cancer, so if a subject was positive, CRC or precancerous lesions of CRC may exist. Product Standard - Cancer Type: Colorectal Cancer - Subject: Subjects for asymptomatic colorectal cancer screening - Biomarker: SDC2 me The price and transaction conditions are negotiable. Please Request a Quote for the transaction

Within medicine the use of polarised light was first introduced back in the70’s; since then it has come leaps and bounds. How it has been used to help with imaging skin pathologies, when the skin is illuminated by linearly polarised light it causes backscattering of the superficial layers of the skin where cancer often arises. This superficial backscattered light can be distinguished from the diffused reflected light when using a detector. Polarised Beam-Splitter Cubes, Sheet Linear Polarisers, and Sheet Circular Polarisers are often used within detection devices for this type of skin pathology imaging. Knight Optical hold a large inventory of Polarisers for use within Skin Cancer Detection devices. •We stock large sheets up to 1270x480mm in some cases; we can cut these into special shapes at short notice. •Mounting options are also available. •Special Glass laminating to CAB polarisers •Special AR coatings. Read PDF for more information

Enzalutamide binds to androgen receptors and thereby inhibits them (antiandrogen). In addition, translocation in the cell nuclei is inhibited and the binding to the DNA is weakened, as well as the recruitment of cofactors for transcription. This leads to the inhibition of gene expression, which are regulated by the androgen receptors. Due to the triple mechanism of action, Enzalutamide differs from the usual anti-androgenic substances. Due to its anti-androgenic properties, the active ingredient also has an antineoplastic effect in androgen-sensitive tumors (e.g. metastatic prostate cancer).